A
Alexander R. Shoemaker
Researcher at Abbott Laboratories
Publications - 29
Citations - 7401
Alexander R. Shoemaker is an academic researcher from Abbott Laboratories. The author has contributed to research in topics: Cancer & Kinase. The author has an hindex of 18, co-authored 28 publications receiving 6912 citations. Previous affiliations of Alexander R. Shoemaker include Neurocrine Biosciences & Idun Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf,Steven W. Elmore,Alexander R. Shoemaker,Robert C. Armstrong,David J. Augeri,Barbara A. Belli,Milan Bruncko,Thomas L. Deckwerth,Jürgen Dinges,Philip J. Hajduk,Mary K. Joseph,Shinichi Kitada,Stanley J. Korsmeyer,Stanley J. Korsmeyer,Kunzer Aaron R,Anthony Letai,Chi Li,Michael J. Mitten,David G. Nettesheim,Shi Chung Ng,Paul Nimmer,Jacqueline M. O'Connor,Anatol Oleksijew,Andrew M. Petros,John C. Reed,Wang Shen,Stephen K. Tahir,Craig B. Thompson,Kevin J. Tomaselli,Baole Wang,Wendt Michael D,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg +33 more
TL;DR: Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation.
Journal ArticleDOI
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Christin Tse,Alexander R. Shoemaker,Jessica Adickes,Mark G. Anderson,Jun Chen,Sha Jin,Eric F. Johnson,Kennan C. Marsh,Michael J. Mitten,Paul Nimmer,Lisa R. Roberts,Stephen K. Tahir,Yu Xiao,Xiufen Yang,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +17 more
TL;DR: The biological properties and rationale for clinical trials evaluating ABT-263 in small-cell lung cancer and B-cell malignancies are provided and the oral efficacy should provide dosing flexibility to maximize clinical utility both as a single agent and in combination regimens are reported.
Journal ArticleDOI
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.
Thorsten Oost,Chaohong Sun,Robert C. Armstrong,Ali-Samer Al-Assaad,Stephen F. Betz,Thomas L. Deckwerth,Hong Ding,Steven W. Elmore,R. P. Meadows,Edward T. Olejniczak,Andrew Oleksijew,Tilman Oltersdorf,Saul H Rosenberg,Alexander R. Shoemaker,Kevin J. Tomaselli,Hua Zou,Stephen W. Fesik +16 more
TL;DR: The present study validates the BIR3 domain of XIAP as a target and supports the use of small molecule XIAP antagonists as a potential therapy for cancers that overexpress XIAP.
Journal ArticleDOI
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
Cheol-Min Park,Milan Bruncko,Jessica Adickes,Joy Bauch,Hong Ding,Kunzer Aaron R,Kennan C. Marsh,Paul Nimmer,Alexander R. Shoemaker,Xiaohong Song,Stephen K. Tahir,Christin Tse,Wang Xilu,Michael D. Wendt,Xiufen Yang,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +18 more
TL;DR: Targeted modifications at three key positions of 1 resulted in a 20-fold improvement in the pharmacokinetic/pharmacodynamic relationship (PK/PD) between oral exposure (AUC) and in vitro efficacy in human tumor cell lines (EC 50).
Journal ArticleDOI
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Milan Bruncko,Thorsten Oost,Barbara A. Belli,Hong Ding,Mary K. Joseph,Kunzer Aaron R,Darlene Martineau,Mcclellan William J,Michael J. Mitten,Shi-Chu Ng ng,Paul Nimmer,Tilman Oltersdorf,Cheol-Min Park,Andrew M. Petros,Alexander R. Shoemaker,Xiaohong Song,Wang Xilu,Wendt Michael D,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +21 more
TL;DR: Compound 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.